Ioversol

Ioversol
Clinical data
Trade names	Optiray
AHFS/Drugs.com	Multum Consumer Information
Pregnancy; category	AU: B1;
ATC code	V08AB07 (WHO) ;
Legal status
Legal status	AU: Unscheduled ;
Pharmacokinetic data
Protein binding	Low
Metabolism	None
Elimination half-life	90 min
Excretion	Kidneys
Identifiers
	IUPAC name 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide;
CAS Number	87771-40-2 ;
PubChem CID	3741;
DrugBank	DB09134 ;
ChemSpider	3610 ;
UNII	N3RIB7X24K;
KEGG	D01555 ;
ChEMBL	ChEMBL1200614 ;
CompTox Dashboard (EPA)	DTXSID2045521 ;
ECHA InfoCard	100.118.911
Chemical and physical data
Formula	C18H24I3N3O9
Molar mass	807.115 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO;
	InChI InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33) ; Key:AMDBBAQNWSUWGN-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ioversol (INN; trade name Optiray) is an organoiodine compound that is used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is used in clinical diagnostics including arthrography, angiocardiography and urography.^[1]^[2]^[3]

References

↑ "Drug Information Portal - U.S. National Library of Medicine - Quick Access to Quality Drug Information". druginfo.nlm.nih.gov. Retrieved 9 January 2021.
↑ "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.
↑ Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Drug-1] "Drug Information Portal - U.S. National Library of Medicine - Quick Access to Quality Drug Information". druginfo.nlm.nih.gov. Retrieved 9 January 2021.

[Medscape-2] "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.

[Chen-3] Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.

[1]

[2]

[3]